Effect of Interferon alpha-2a malignant mesothelioma

T.I. Christmas, L.S. Manning, M.J. Garlepp, A.W. Musk, Bruce Robinson

Research output: Contribution to journalArticle

74 Citations (Scopus)

Abstract

Malignant mesothelioma (MM) is a tumor that is resistant to conventional therapy. Interferon-alpha (IFN-alpha) has been used in the treatment of some human tumors, and we have previously demonstrated an in vitro anti-proliferative effect of IFN against MM cell lines. Therefore, the effect of recombinant human IFN-alpha (IFN-alpha2a) (Roferon-A, Hoffmann-La Roche) on previously untreated patients with MM has been studied. Twenty-five patients (24 male and 1 female), with a mean age of 59 +/- 9.9 years, were treated for 3 months with IFN-alpha2a. The starting dose was 3 x 10(6) IU daily increasing to a maximum of 18 x 10(6) IU daily or as tolerated. All patients had measurable tumor on thoracic CT prior to commencement. CT scans were performed at 6 and 12 weeks to determine tumor response. Twenty patients completed 3 months of treatment. Five patients were withdrawn because of disease progression. Side effects were predictable and dose related. Dose reductions were necessary in 12 patients for grade 2 toxicity. One patient had a complete response (CR), 2 patients had partial responses (PR) (response rate = 12%), 13 (52%) patients remained stable, 1 of whom exhibited a delayed PR, and 9 (36%) had progressive disease. These data suggest that IFN-alpha2a is well tolerated in patients with MM and is active against MM in a proportion of patients.
Original languageEnglish
Pages (from-to)9-12
JournalJournal of Interferon Research
Volume13
DOIs
Publication statusPublished - 1992

Fingerprint

Interferon-alpha
Neoplasms
interferon alfa-2a
Malignant Mesothelioma
Disease Progression
Thorax
Therapeutics
Cell Line
In Vitro Techniques

Cite this

Christmas, T.I. ; Manning, L.S. ; Garlepp, M.J. ; Musk, A.W. ; Robinson, Bruce. / Effect of Interferon alpha-2a malignant mesothelioma. In: Journal of Interferon Research. 1992 ; Vol. 13. pp. 9-12.
@article{77229a28ed5145488e8727ac167cafe0,
title = "Effect of Interferon alpha-2a malignant mesothelioma",
abstract = "Malignant mesothelioma (MM) is a tumor that is resistant to conventional therapy. Interferon-alpha (IFN-alpha) has been used in the treatment of some human tumors, and we have previously demonstrated an in vitro anti-proliferative effect of IFN against MM cell lines. Therefore, the effect of recombinant human IFN-alpha (IFN-alpha2a) (Roferon-A, Hoffmann-La Roche) on previously untreated patients with MM has been studied. Twenty-five patients (24 male and 1 female), with a mean age of 59 +/- 9.9 years, were treated for 3 months with IFN-alpha2a. The starting dose was 3 x 10(6) IU daily increasing to a maximum of 18 x 10(6) IU daily or as tolerated. All patients had measurable tumor on thoracic CT prior to commencement. CT scans were performed at 6 and 12 weeks to determine tumor response. Twenty patients completed 3 months of treatment. Five patients were withdrawn because of disease progression. Side effects were predictable and dose related. Dose reductions were necessary in 12 patients for grade 2 toxicity. One patient had a complete response (CR), 2 patients had partial responses (PR) (response rate = 12{\%}), 13 (52{\%}) patients remained stable, 1 of whom exhibited a delayed PR, and 9 (36{\%}) had progressive disease. These data suggest that IFN-alpha2a is well tolerated in patients with MM and is active against MM in a proportion of patients.",
author = "T.I. Christmas and L.S. Manning and M.J. Garlepp and A.W. Musk and Bruce Robinson",
year = "1992",
doi = "10.1089/jir.1993.13.9",
language = "English",
volume = "13",
pages = "9--12",
journal = "Journal of Interferon Research",
issn = "0197-8357",
publisher = "Mary Ann Liebert Inc",

}

Effect of Interferon alpha-2a malignant mesothelioma. / Christmas, T.I.; Manning, L.S.; Garlepp, M.J.; Musk, A.W.; Robinson, Bruce.

In: Journal of Interferon Research, Vol. 13, 1992, p. 9-12.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Effect of Interferon alpha-2a malignant mesothelioma

AU - Christmas, T.I.

AU - Manning, L.S.

AU - Garlepp, M.J.

AU - Musk, A.W.

AU - Robinson, Bruce

PY - 1992

Y1 - 1992

N2 - Malignant mesothelioma (MM) is a tumor that is resistant to conventional therapy. Interferon-alpha (IFN-alpha) has been used in the treatment of some human tumors, and we have previously demonstrated an in vitro anti-proliferative effect of IFN against MM cell lines. Therefore, the effect of recombinant human IFN-alpha (IFN-alpha2a) (Roferon-A, Hoffmann-La Roche) on previously untreated patients with MM has been studied. Twenty-five patients (24 male and 1 female), with a mean age of 59 +/- 9.9 years, were treated for 3 months with IFN-alpha2a. The starting dose was 3 x 10(6) IU daily increasing to a maximum of 18 x 10(6) IU daily or as tolerated. All patients had measurable tumor on thoracic CT prior to commencement. CT scans were performed at 6 and 12 weeks to determine tumor response. Twenty patients completed 3 months of treatment. Five patients were withdrawn because of disease progression. Side effects were predictable and dose related. Dose reductions were necessary in 12 patients for grade 2 toxicity. One patient had a complete response (CR), 2 patients had partial responses (PR) (response rate = 12%), 13 (52%) patients remained stable, 1 of whom exhibited a delayed PR, and 9 (36%) had progressive disease. These data suggest that IFN-alpha2a is well tolerated in patients with MM and is active against MM in a proportion of patients.

AB - Malignant mesothelioma (MM) is a tumor that is resistant to conventional therapy. Interferon-alpha (IFN-alpha) has been used in the treatment of some human tumors, and we have previously demonstrated an in vitro anti-proliferative effect of IFN against MM cell lines. Therefore, the effect of recombinant human IFN-alpha (IFN-alpha2a) (Roferon-A, Hoffmann-La Roche) on previously untreated patients with MM has been studied. Twenty-five patients (24 male and 1 female), with a mean age of 59 +/- 9.9 years, were treated for 3 months with IFN-alpha2a. The starting dose was 3 x 10(6) IU daily increasing to a maximum of 18 x 10(6) IU daily or as tolerated. All patients had measurable tumor on thoracic CT prior to commencement. CT scans were performed at 6 and 12 weeks to determine tumor response. Twenty patients completed 3 months of treatment. Five patients were withdrawn because of disease progression. Side effects were predictable and dose related. Dose reductions were necessary in 12 patients for grade 2 toxicity. One patient had a complete response (CR), 2 patients had partial responses (PR) (response rate = 12%), 13 (52%) patients remained stable, 1 of whom exhibited a delayed PR, and 9 (36%) had progressive disease. These data suggest that IFN-alpha2a is well tolerated in patients with MM and is active against MM in a proportion of patients.

U2 - 10.1089/jir.1993.13.9

DO - 10.1089/jir.1993.13.9

M3 - Article

VL - 13

SP - 9

EP - 12

JO - Journal of Interferon Research

JF - Journal of Interferon Research

SN - 0197-8357

ER -